Legal Opinion

In re Kerydin (Tavaborole) Topical Solution 5% Patent Litig.

United States Judicial Panel on Multidistrict Litigation

Decided April 3, 2019No. MDL No. 2884Published

1Opinion of the Court

SARAH S. VANCE, Chair

Before the Panel:* Plaintiff and patentholder Anacor Pharmaceuticals, Inc., invokes 28 U.S.C. § 1407 to seek centralization of this patent infringement litigation in the District of Delaware. This litigation consists of three actions pending in two districts, as listed on Schedule A. Generic manufacturer defendants1 in two D. Delaware actions do not oppose centralization in the District of Delaware. Mylan Inc., and Mylan Pharmaceuticals Inc. (collectively, Mylan), which are defendants in the Northern District of West Virginia action, oppose centralization.

*1371Anacor filed…

2Cases cited6 opinions

  1. Eli Lilly & Co. v. Medtronic, Inc.Supreme Court of the United States · 1990
  2. Teva Pharmaceuticals USA, Inc. v. SebeliusCourt of Appeals for the D.C. Circuit · 2010
  3. In Re Brimonidine Patent LitigationUnited States Judicial Panel on Multidistrict Litigation · 2007
  4. In Re Metoprolol Succinate Patent Lit.United States Judicial Panel on Multidistrict Litigation · 2004
  5. In Re ALFUZOSIN HYDROCHLORIDE PATENT LITIGATIONUnited States Judicial Panel on Multidistrict Litigation · 2008

1 more not listed; retrieve them via the Exa API.

Showing a preview — retrieve the full document via the Exa API.

Powered by the Exa API